We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 18, 2019

Adjuvant Ipilimumab vs Placebo After Complete Resection of Stage III Melanoma

European Journal of Cancer


Additional Info

European Journal of Cancer
Adjuvant Ipilimumab Versus Placebo After Complete Resection of Stage III Melanoma: Long-Term Follow-Up Results of the European Organisation for Research and Treatment of Cancer 18071 Double-Blind Phase 3 Randomised Trial
Eur. J. Cancer 2019 Sep 01;119(xx)1-10, AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, H Schmidt, O Hamid, C Robert, PA Ascierto, JM Richards, C Lebbe, V Ferraresi, M Smylie, JS Weber, M Maio, F Hosein, V de Pril, M Kicinski, S Suciu, A Testori

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading